Search

Your search keyword '"Haralabos Eleftheriadis"' showing total 3 results
Start Over Author "Haralabos Eleftheriadis" Journal bmj open
3 results on '"Haralabos Eleftheriadis"'

1. Subthreshold micropulse laser versus standard laser for the treatment of central-involving diabetic macular oedema with central retinal thickness of

Author

Sobha Sivaprasad, Clare Bailey, Augusto Azuara-Blanco, Mike Clarke, Danny Mcauley, Louise Downey, Noemi Lois, Norman Waugh, Hema Mistry, Victor Chong, Faruque Ghanchi, Ahmed Saad, David H Steel, Geeta Menon, Haralabos Eleftheriadis, Nachiketa Acharya, Samia Fatum, Tariq M Aslam, Paul Doherty, Sheena George, Robin Hamilton, Catherine Adams, Clíona McDowell, Markus Groppe, James Stephen Talks, Mandy Maredza, Marianne Shiew, Christina Campbell, Evie Gardener, Aby Joseph, and Matthew Mills

Subjects
Medicine
Abstract

Objectives To estimate the economic costs, health-related quality-of-life outcomes and cost-effectiveness of subthreshold micropulse laser (SML) versus standard laser (SL) for the treatment of diabetic macular oedema (DMO) with central retinal thickness (CRT) of

Published
2023
Full Text
View/download PDF

2. Estimating excess visual loss from neovascular age-related macular degeneration in the UK during the COVID-19 pandemic: a retrospective clinical audit and simulation model

Author

Anthony Khawaja, Andrew Lotery, Adnan Tufail, Paul Taylor, Philipp L Müller, Sudeshna Patra, R Khan, E Wilkinson, B Paul, Haralabos Eleftheriadis, Robin Hamilton, S George, V Kumar, R Mukherjee, C Jones, Abraham Olvera-Barrios, Catherine Egan, Roy Schwartz, C Brand, H Palmer, Alasdair Warwick, C Bailey, U Chakravarthy, F Ghanchi, S Mahmood, A Davis, L Downey, G Menon, N Dhingra, R Antcliff, A Lobo, A Patwardhan, T Akerele, Darren S Thomas, Ella Preston, P Lip, S Natha, and J Talks

Subjects
Medicine
Abstract

Objectives To report the reduction in new neovascular age-related macular degeneration (nAMD) referrals during the COVID-19 pandemic and estimate the impact of delayed treatment on visual outcomes at 1 year.Design Retrospective clinical audit and simulation model.Setting Multiple UK National Health Service (NHS) ophthalmology centres.Participants Data on the reduction in new nAMD referrals were obtained from four NHS Trusts comparing April 2020 with April 2019. To estimate the potential impact on 1-year visual outcomes, a stratified bootstrap simulation model was developed drawing on an electronic medical records dataset of 20 825 nAMD eyes from 27 NHS Trusts.Main outcome measures Simulated mean visual acuity and proportions of eyes with vision ≤6/60, ≤6/24 and ≥6/12 at 1 year under four hypothetical scenarios: 0-month, 3-month, 6-month and 9-month treatment delays. Estimated additional number of eyes with vision ≤6/60 at 1 year nationally.Results The number of nAMD referrals dropped on average by 72% (range 65%–87%). Simulated 1-year visual outcomes for 1000 nAMD eyes with a 3-month treatment delay suggested an increase in the proportion of eyes with vision ≤6/60 from 15.5% (13.2%–17.9%) to 23.3% (20.7%–25.9%), and a decrease in the proportion of eyes with vision ≥6/12 (driving vision) from 35.1% (32.1%–38.1%) to 26.4% (23.8%–29.2%). Outcomes worsened incrementally with longer modelled delays. Assuming nAMD referrals are reduced to this level for 1 month nationally, these simulated results suggest an additional 186–365 eyes with vision ≤6/60 at 1 year.Conclusions We report a large decrease in nAMD referrals during the COVID-19 lockdown and provide an important public health message regarding the risk of delayed treatment. As a conservative estimate, a treatment delay of 3 months could lead to a >50% relative increase in the number of eyes with vision ≤6/60 and 25% relative decrease in the number of eyes with driving vision at 1 year.

Published
2022
Full Text
View/download PDF

3. Estimating excess visual loss from neovascular age-related macular degeneration in the UK during the COVID-19 pandemic: a retrospective clinical audit and simulation model

Author

Darren S, Thomas, Alasdair, Warwick, Abraham, Olvera-Barrios, Catherine, Egan, Roy, Schwartz, Sudeshna, Patra, Haralabos, Eleftheriadis, Anthony, Khawaja, Andrew, Lotery, Philipp L, Muller, Robin, Hamilton, Ella, Preston, Paul, Taylor, Adnan, Tufail, and E, Wilkinson

Subjects
Clinical Audit, genetic structures, Vision Disorders, COVID-19, Angiogenesis Inhibitors, General Medicine, State Medicine, United Kingdom, eye diseases, Macular Degeneration, Treatment Outcome, Ranibizumab, Communicable Disease Control, Intravitreal Injections, Wet Macular Degeneration, Humans, Pandemics, Retrospective Studies
Abstract

ObjectivesTo report the reduction in new neovascular age-related macular degeneration (nAMD) referrals during the COVID-19 pandemic and estimate the impact of delayed treatment on visual outcomes at 1 year.DesignRetrospective clinical audit and simulation model.SettingMultiple UK National Health Service (NHS) ophthalmology centres.ParticipantsData on the reduction in new nAMD referrals were obtained from four NHS Trusts comparing April 2020 with April 2019. To estimate the potential impact on 1-year visual outcomes, a stratified bootstrap simulation model was developed drawing on an electronic medical records dataset of 20 825 nAMD eyes from 27 NHS Trusts.Main outcome measuresSimulated mean visual acuity and proportions of eyes with vision ≤6/60, ≤6/24 and ≥6/12 at 1 year under four hypothetical scenarios: 0-month, 3-month, 6-month and 9-month treatment delays. Estimated additional number of eyes with vision ≤6/60 at 1 year nationally.ResultsThe number of nAMD referrals dropped on average by 72% (range 65%–87%). Simulated 1-year visual outcomes for 1000 nAMD eyes with a 3-month treatment delay suggested an increase in the proportion of eyes with vision ≤6/60 from 15.5% (13.2%–17.9%) to 23.3% (20.7%–25.9%), and a decrease in the proportion of eyes with vision ≥6/12 (driving vision) from 35.1% (32.1%–38.1%) to 26.4% (23.8%–29.2%). Outcomes worsened incrementally with longer modelled delays. Assuming nAMD referrals are reduced to this level for 1 month nationally, these simulated results suggest an additional 186–365 eyes with vision ≤6/60 at 1 year.ConclusionsWe report a large decrease in nAMD referrals during the COVID-19 lockdown and provide an important public health message regarding the risk of delayed treatment. As a conservative estimate, a treatment delay of 3 months could lead to a >50% relative increase in the number of eyes with vision ≤6/60 and 25% relative decrease in the number of eyes with driving vision at 1 year.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results